PRINCETON, N.J., and PARIS, Feb. 23, 2011 — STENTYS S.A. (STNT.PA)announced today that it has received a higher price reimbursement in Germany for its drug-eluting stent.
“This decision not only fortifies our ongoing commercialization activities in Germany, the largest European market,” said Gonzague Issenmann, CEO and co-founder of STENTYS, “but it is also a clear recognition of the innovation and patient benefit of the STENTYS technology.”
The Institute for the Hospital Remuneration System (InEK) granted this special status of “new and innovative device” (Neue Untersuchungs- und Behandlungsmethoden, or “NUB”) to the STENTYS stent for 2011.
Of note: the STENTYS self-apposing stent represents a major breakthrough compared to conventional stents when treating heart attacks: it “fits snugly” into the contour of a blood vessel and adapts to the anatomic changes of the coronary arteries during the post-AMI phase, eliminating malapposition which exposes patients to serious risk of recurrence of the heart attack.
About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevent the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.
This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
